JXN vs MET

Key Takeaways

• Jackson Financial Inc. (JXN) is a U.S.-focused retirement annuity provider with an ~$8.3 billion market cap, while MetLife, Inc. (MET) is a diversified global insurance and financial services giant valued at approximately $61 billion.
• In recent months, JXN has delivered stronger price momentum, gaining roughly 41% over the trailing 12 months, compared to approximately 26% for MET.
• JXN posted record retail annuity sales of $19.7 billion in 2025 alongside aggressive share buybacks, while MET benefits from a globally diversified revenue base and improving international sales momentum.
• JXN carries a higher beta (1.33) and a negative GAAP P/E ratio due to reinsurance-related accounting impacts, whereas MET trades at a traditional P/E of roughly 18 and features a lower beta of 0.78.
• Both companies return substantial capital to shareholders; JXN targets $900 million to $1.1 billion in capital returns for 2026, while MET returned approximately $900 million in a single quarter.

Introduction

Comparing JXN and MET places two very different insurance-sector companies side by side. Jackson Financial is a concentrated, U.S.-centric annuity powerhouse, while MetLife is one of the largest and most geographically diversified insurers in the world. Both compete in overlapping retirement and protection markets, yet their scale, business mix, and risk profiles diverge meaningfully. This stock comparison is especially relevant for investors evaluating the trade-off between focused domestic growth and global diversification, or those seeking to understand how recent market conditions have shaped relative performance across the insurance landscape.

JXN Overview and Recent Performance

JXN, or Jackson Financial Inc., is a Lansing, Michigan-based retirement services company that primarily offers variable annuities, registered index-linked annuities (RILAs), fixed and fixed index annuities, and institutional products. The company operates through three segments: Retail Annuities, Institutional Products, and Closed Life and Annuity Blocks. In recent weeks, JXN shares have traded near $119, reflecting a climb of more than 40% over the past year. The stock's 52-week range spans from approximately $83 to nearly $127.

Driving sentiment has been a series of strong operational results. For full-year 2025, Jackson reported record retail annuity sales of $19.7 billion, up 10% from the prior year, alongside record RILA sales of $6.9 billion. Adjusted operating earnings reached $1.6 billion, or $22.67 per diluted share. The company's risk-based capital (RBC) ratio — a key measure of an insurer's financial strength — stood at 567%, well above regulatory minimums. Jackson also exceeded its capital return targets in 2025, returning $862 million to common shareholders through repurchases and dividends, and has set a 2026 capital return target of $900 million to $1.1 billion. A newly announced strategic partnership with TPG and enhanced asset-sourcing capabilities at subsidiary PPM America have further supported the positive outlook. However, GAAP (Generally Accepted Accounting Principles) net income has been volatile due to mark-to-market impacts on reinsured business, resulting in a negative trailing P/E ratio.

MET Overview and Recent Performance

MET, or MetLife, Inc., is a New York-based global financial services company providing insurance, annuities, employee benefits, and asset management across more than 40 markets. Its six operating segments — Group Benefits, Retirement and Income Solutions (RIS), Asia, Latin America, EMEA (Europe, the Middle East, and Africa), and MetLife Holdings — generate over $77 billion in annual revenue. In recent weeks, MET shares have traded around $95, up roughly 26% over the trailing 12 months, with a 52-week range between roughly $67 and $95.

MetLife's recent performance has been characterized by mixed quarterly results. In the third quarter of 2025, adjusted earnings per share grew 21% year-over-year to $2.34, driven by strong variable investment income, volume growth, and expense discipline. The Asia segment stood out with sales growth of 34% on a constant currency basis, while the Retirement and Income Solutions segment secured $12 billion in pension risk transfer (PRT) mandates. Adjusted return on equity (ROE) improved to 16.9% in Q3 2025, up from 14.6% in the prior quarter. However, earlier in 2025, underwriting headwinds in Group Benefits and lower private equity returns pressured earnings. With a market cap near $61 billion, a P/E ratio around 18, and a beta of 0.78, MET represents the larger, more diversified, and lower-volatility option in this comparison.

Trending AI Robots

For traders seeking an automated, data-driven approach to navigating stock selections like JXN and MET, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. While Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, only those demonstrating the strongest adaptability to current market conditions earn a spot in this featured section. The bots span a wide range of trading styles, timeframes, and strategies — from short-term momentum to longer-duration trend-following — and each bot displays transparent performance statistics including win rates, total trades, and return figures. These bots are designed to analyze technical indicators, pattern formations, and volume signals in real time, helping traders identify opportunities without emotional bias. Explore the Trending AI Robots page to see which automated strategies are currently positioned for today's market conditions.

Head-to-Head Comparison

The most fundamental contrast between JXN and MET lies in scope and diversification. JXN is a focused annuity specialist — its fortunes are closely tied to U.S. retirement savings trends, equity market levels (which influence variable annuity fee income), and interest rate spreads. This concentration has been an advantage in a strong U.S. equity and rate environment, fueling record sales and robust adjusted earnings. However, it also means that a downturn in U.S. markets or a prolonged low-rate cycle would disproportionately affect Jackson's business.

MET, by contrast, derives revenue from group life and disability insurance, international life and health products, retirement solutions, and a growing asset management arm (MetLife Investment Management, with over $200 billion in institutional client AUM, or assets under management). Its global footprint — spanning Asia, Latin America, and EMEA — provides natural hedges against any single region's economic cycle. This diversification has helped MetLife deliver steadier, though generally slower, growth. On risk metrics, JXN's higher beta of 1.33 reflects greater sensitivity to market swings, while MET's beta of 0.78 signals relative stability.

Capital return is a shared strength but takes different forms. JXN has been aggressively repurchasing shares — reducing its diluted share count by roughly a third since becoming independent in 2021 — which amplifies per-share metrics. MET also returns billions annually but distributes capital across a much larger equity base, meaning the per-share impact is less dramatic. On valuation, JXN screens differently depending on whether one uses GAAP net income (negative P/E) or adjusted operating earnings, while MET trades at a conventional P/E multiple near 18, in line with large-cap insurer peers.

Tickeron AI Verdict

Based on observable trend consistency, momentum patterns, and relative positioning, Tickeron's AI-driven analysis would likely lean toward JXN in the current environment. The stock's sustained price uptrend, record-breaking sales growth in RILA products, aggressive share buyback activity, and management's upwardly revised capital return targets create a compelling momentum profile. However, this preference comes with an important caveat: JXN's higher beta and business concentration introduce greater potential drawdown risk during market volatility. For traders prioritizing trend strength and willing to accept higher variability, JXN presents a more dynamic opportunity set. For those favoring stability, global diversification, and more predictable earnings streams, MET remains the steadier alternative. The AI's probabilistic assessment reflects these trade-offs rather than a definitive judgment on either stock's absolute merit.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations